New and emerging treatments for ulcerative colitis: a focus on vedolizumab

References

• OrdásIEckmannLTalaminiMBaumgartDCSandbornWJUlcerative colitisLancet201238098531606161922914296
   PubMed Web of Science ®Google Scholar
• D’HaensGSandbornWJFeaganBGA review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitisGastroenterology2007132276378617258735
   PubMed Web of Science ®Google Scholar
• DignassALindsayJOSturmASecond European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current managementJ Crohns Colitis2012610991103023040451
   PubMed Web of Science ®Google Scholar
• RutgeertsPSandbornWJFeaganBGInfliximab for induction and maintenance therapy for ulcerative colitisN Engl J Med2005353232462247616339095
   PubMed Web of Science ®Google Scholar
• ReinischWSandbornWJHommesDWAdalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut201160678078721209123
   PubMed Web of Science ®Google Scholar
• TaxoneraCEstellésJFernández-BlancoIAdalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximabAliment Pharmacol Ther201133334034821133961
   PubMed Web of Science ®Google Scholar
• McDermottEMurphySKeeganDO’DonoghueDMulcahyHDohertyGEfficacy of Adalimumab as a long term maintenance therapy in ulcerative colitisJ Crohns Colitis Epub April 18, 2012
   Web of Science ®Google Scholar
• DaneseSNew therapies for inflammatory bowel disease: from the bench to the bedsideGut201261691893222115827
   PubMed Web of Science ®Google Scholar
• BehmBWBickstonSJHumanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitisCochrane Database Syst Rev20091CD00757119160337
   PubMed Web of Science ®Google Scholar
• TilgHKaserAVedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn’s diseaseCurr Opin Investig Drugs2010111112951304
   PubMedGoogle Scholar
• SouzaHSEliaCCSpencerJMacDonaldTTExpression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel diseaseGut199945685686310562584
   PubMed Web of Science ®Google Scholar
• ArihiroSOhtaniHSuzukiMDifferential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn’s diseasePathol Int2002525–636737412100519
   PubMed Web of Science ®Google Scholar
• MeenanJSpaansJGroolTAPalsSTTytgatGNvan DeventerSJAltered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammationGut19974022412469071939
   PubMed Web of Science ®Google Scholar
• MonteleoneGCaprioliFWhy are molecular mechanisms of immune activation important in IBD?Inflam Bowel Dis200814Suppl 2S106S107
   Google Scholar
• CavigliaRBoskoskiICicalaMMaintenance treatment with infliximab for the management of Crohn’s disease in adultsBiologics20093394919707394
   PubMedGoogle Scholar
• CassinottiAArdizzoneSPorroGBAdalimumab for the treatment of Crohn’s diseaseBiologics20082476377719707457
   PubMedGoogle Scholar
• MarshallJKLDP-02 (Millenium)Curr Opin Investig Drugs200124502504
   PubMedGoogle Scholar
• HesterbergPEWinsor-HinesDBriskinMJRapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7Gastroenterology19961115137313808898653
   PubMed Web of Science ®Google Scholar
• van AsscheGRutgeertsPAntiadhesion molecule therapy in inflammatory bowel diseaseInflam Bowel Dis200284291300
   PubMed Web of Science ®Google Scholar
• FeaganBMacdonaldJGreenbergGAn ascending dose of a humanized alpha 4 beta 7 antibody in ulcerative colitis (UC)Gastroenterology20001184A874
   Web of Science ®Google Scholar
• BaronJHCornellAMLennard-JonesJEVariation between observers in describing mucosal appearances in proctocolitisBMJ1964111899214075156
   PubMed Web of Science ®Google Scholar
• SchroederKWTremaineWJIlstrupDMCoated oral 5-aminoscilyclic-acid therapy for mild to moderately active ulcerative colitisNew England Journal of Medicine198731726162516293317057
   PubMed Web of Science ®Google Scholar
• FeaganBGGreenbergGRWildGTreatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrinN Engl J Med2005352242499250715958805
   PubMed Web of Science ®Google Scholar
• ParikhALeachTWyantTVedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging studyInflam Bowel Dis201118814701479
   Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE)Infliximab for Acute Exacerbations of Ulcerative ColitisNICE technology appraisal guidance 163LondonNICE2008 [updated 2011]. Available from: http://www.nice.org.uk/nicemedia/pdf/TA163Guidance.pdfAccessed January 22, 2013
   Google Scholar
• NICEInfliximab for Subacute Manifestations of Ulcerative ColitisNICE technology appraisal guidance 140LondonNICE2008 Available from: http://www.nice.org.uk/nicemedia/pdf/TA140Guidance.pdfAccessed January 22, 2013
   Google Scholar
• ParikhALeachTXuJFeaganBP235. Long-term clinical experience with vedolizumab (VDZ) in patients with mild to moderate ulcerative colitis (UC)J Crohns Colitis20126Supp 1S103
   Google Scholar
• FeaganBRutgeertsPSandsJ943b Induction therapy for ulcerative colitis: results of GEMINI I, a randomised placebo-controlled, double-blind, multicentre phase 3 trialGastroenterology20121425S160S161
   Google Scholar
• RutgeertsPVedolizumab induction therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicentre phase 3 trialGut20122012Supp 3A65
   Google Scholar
• RutgeertsPVedolizumab maintenance therapy for ulcerative colitis (uc): results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trialGut201261Supp 3A65
   Google Scholar
• ReichertJMAntibody-based therapeutics to watch in 2011MAbs201131769921051951
   PubMed Web of Science ®Google Scholar
• DaneseSDe La RueSAGasbarriniAAntibody to α4β7 integrin for ulcerative colitisN Engl J Med200535511118016162892
   PubMed Web of Science ®Google Scholar
• AllenPBAnti-adhesion molecules: is gut specificity the key for a good safety profile?Curr Drug Deliv20129433333722762276
   PubMed Web of Science ®Google Scholar
• CohenRDMLN-02 in IBD: is “super-selective” really super?Gastroenterology200613061923192416697759
   PubMed Web of Science ®Google Scholar
• SolerDChapmanTYangLLWyantTEganRFedykERThe binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseasesJ Pharmacol Exp Ther2009330386487519509315
   PubMed Web of Science ®Google Scholar
• ParikhAFedykESolerDGastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to alpha4beta7 integrin: P–0025Inflamm Bowel Dis200814S1818816687
   PubMed Web of Science ®Google Scholar
• FedykERWyantTYangLLExclusive antagonism of the α(4) β(7) integrin by vedolizumab confirms the gut-selectivity of this pathway in primatesInflam Bowel Dis Epub March 14, 2012
   Web of Science ®Google Scholar
• FedykECsizmadiaVShyuWYangLWyantTKadambiVThe gastrointestinal-selective biologic vedolizumab does not impair immune surveillance of the central nervous system in non-human primates: O-015Inflamm Bowel Dis201117S4S5
   Web of Science ®Google Scholar
• MilchCWyantTXuJKentWBergerJFoxIHP234. Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteersJ Crohns Colitis20126S102S103
   Google Scholar
• ParikhAWyantTCliffordD1008 No increase in JC viremia, lymphocyte count, or circulating CD34+ hematopoietic progenitor cells after treatment with vedolizumab, a humanized monoclonal antibody to α4β7 integrinGastroenterology20101385 Suppl 1S145S146
   Web of Science ®Google Scholar
• FeaganBGGreenbergGRWildGTreatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrinClin Gastroenterol Hepatol20086121370137718829392
   PubMed Web of Science ®Google Scholar